VOI - Voice of Indonesia | RRI - Radio Republik Indonesia

The Chinese Academy of Sciences (CAS) claims the COVID-19 vaccine developed by the Institute of Microbiology is safe for humans, according to the results of clinical trials by the institute.

The results of phase I and phase II trials have resulted in safety and health for people who received the vaccine injection and found no serious side effects, the Institute of Microbiology, an institution under CAS, was quoted by local media on Monday.

The Institute of Microbiology in collaboration with Chongqing Zhifei Biological Products Co Ltd has obtained permission to develop the COVID-19 vaccine from the Chinese National Medical Products Agency (NMPA) on June 19.

Researchers began conducting clinical trials on June 23 to make sure the vaccine is safe to administer to humans. The volunteers who are willing to receive the vaccine are aged 18-59 years from Beijing, Chongqing, and Hunan.

They received injections at hospitals in Beijing and Chongqing.

Then a second clinical trial was conducted on July 10 to evaluate the immunity power and safety of the vaccine. According to the development agency, clinical trials are conducted randomly to determine the effectiveness of vaccines before they are mass-produced.

The vaccine is patented and the developer is preparing a phase III clinical trial to confirm its efficacy. To date, in China, there have been 13 COVID-19 vaccines developed by several research institutes and pharmaceutical manufacturers.

The Chinese Ministry of Science and Technology said that there have been four COVID-19 vaccine candidates that have conducted fae III clinical trials.

Chinese people are looking forward to the vaccine. Sinovac and Sinopharm, China's largest vaccine company, recently started offering a limited amount via online platforms. (Antaranews)